Background: Most diagnosed pancreatic neuroendocrine tumors (pNETs) are nonfunctioning tumors (90.8%); the remaining 9% are malignant functioning tumors. While surgical resection is the standard of care, alternative management options may be mandated in symptomatic patients who refuse or are ineligible for surgery. We present a case of endoscopic ultrasound (EUS)-guided ethanol ablation of symptomatic insulinoma in a patient who refused surgery. Case Presentation: A 35-year-old man was referred to our facility with suspected insulinoma for EUS evaluation. During a 48-h supervised fast, a plasma glucose of 30 mg/ dl was obtained with a corresponding serum insulin level of 235 µIU/mL (normal: 20-80) and C-peptide level of 19.9 ng/mL (normal: 2.8-9.9). Computed tomography abdomen revealed a normal pancreas with no detected masses. On admission, he was on intravenous glucose 25% at an infusion rate of 250 mL/h and octreotide (150 mcg subcutaneously three times daily). EUS examination revealed a small hypoechoic pancreatic tail mass 2 cm ×1.5 cm with no vascular involvement or detected lymph nodes. EUS-fine needle aspiration was done using a 25G needle. Pathological examination was consistent with NET. The patient's family initially refused surgery; EUS-guided ethanol ablation was therefore considered. The lesion was injected with 3 mL of ethanol using 25G needle resulting in a hyperechoic blush within the center of the tumor. Following the procedure, there was partial clinical success with the patient's glucose infusion rate decreased to 100 mL/h. After 3 days, a second session was considered. The lesion was re-injected with 3 mL of ethanol using 22G needle resulting in a hyperechoic blush of the lesion. Again, there was partial clinical success with the patient's glucose infusion rate decreased to 50 mL/h. There were no postprocedural complications. The patient's family decided to do surgery and distal pancreatectomy was done. Discussion: EUS-guided ethanol ablation of functioning pNETs is a less common therapeutic tool. A recent literature review showed 19 patients who underwent EUS-guided ethanol ablation of functioning pNETs from 2006 to 2015 with technical and clinical success in 100% of cases. This case reports another EUS-guided ethanol ablation of functioning insulinoma added to the documented cases, with partial clinical success. Despite partial clinical success, EUS-guided ethanol ablation is feasible and safe when applied to symptom relief in functioning tumors in patients who refuse or are ineligible for surgery.
Background and Objectives:
In the perspective of improving accuracy of endoscopic ultrasound (EUS)-guided sampling, the efforts of innovation have focused on needle design, with the development of micro-core acquisition technology, and puncture technique variations. Available studies have shown that fine needle biopsy (FNB) needles can achieve a satisfactory diagnostic yield after fewer passes when compared to fine needle aspiration (FNA) needles, without an overall diagnostic advantage. Limited data are available to explain these results. We compared FNA and side-beveled FNB needles for micro-core/cellular material retrieval and diagnostic performance in pancreatic solid lesions. Methods: This was a single-center retrospective study of 110 consecutive patients who underwent EUSsampling for a solid pancreatic lesion. All cellular material was collected for cell-block construction. The cytological examination was performed according to Papanicolaou. KRAS analysis was used as an ancillary technique to resolve indeterminate cases. Sensitivity and specificity were calculated in FNA (EchoTip ® Ultra) and in FNB (EchoTip ProCore ® ) categories. All cases were evaluated for cellularity and micro-core (fragment retaining tissue architecture) retrieval. We compared FNA and FNB needles of different diameter (FNA: 19, 22, and 25G and FNB: 20, 22, and 25G) , as well as large (19-20G) and small bore needles (22-25G). Results: Considering only positive cytology as diagnostic for malignancy, FNB needles showed higher sensitivity than FNA needles (86.4% vs. 54.9%, P = 0.002). If KRAS-mutated indeterminate cases were considered as malignant, overall sensitivity was 94.7%. In subcategories (FNB vs. FNA), sensitivity was 97.7% versus 92.2%, P = 0.37. Micro-cores were present in 65.2% of FNB versus 15.1% of FNA samples (P < 0.0001), rising to 95.2% in 20G-FNB category, and in 88.5% of large bore versus 20.5% of small bore needles (P < 0.0001). Considering the
